Celularity Inc. (Class A) (CELU) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Per the Roarable RQD rating, CELU scores 26 out of 100 and receives a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 5 / 20. Per the RQD rating, this reflects ROIC of -35% and FCF yield of 0%. The pillar is the weakest of the five on a direct earnings-power basis, indicating the business is not currently generating returns on invested capital or free cash flow.
• Whale 13F Flow: 4 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. The low score suggests limited institutional support in the available signal set.
• Insider Conviction: 3 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, suggesting insider and congressional activity does not offer a supportive signal.
• Macro Regime Fit: 6 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity considered. The score indicates limited alignment with the current macro regime as measured by this model.
• Forensic Balance Sheet: 8 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. The Piotroski reading is weak, and the Altman figure sits in the range the rating treats as a financial-distress signal risk requires attention to.

For a prospective investor, the practical implication is that the rating's composite picture is dominated by negative operating economics. The stock's 52-week range of $0.56 to $2.55 and the current $0.85 price show substantial volatility; a low share price does not by itself indicate value, and the RQD scores point to an elevated risk profile that would need to be weighed against any potential upside drivers in the news flow. Valuation multiples (P/E, EV/EBITDA) are not available in the source data, so a standard valuation tradeoff cannot be assessed from these sources.

Per the SEC financials, every reported period shows negative operating and net income. Per the market data, the operating margin and net margin are each -60%, the gross margin is 24.4%, and ROIC is -35%. The RQD rating reports an Altman Z-Score of 2.5 and a Piotroski F-Score of 1/9, with Debt/Equity of 0.5; the Piotroski reading is weak, and the balance sheet figures are only partially reported in the financial table (debt is N/A across periods).

Per the recent news feed, the headlines emphasize regained Nasdaq compliance. Items flagged as catalysts include "Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement," "All three of Celularity's Nasdaq compliance issues are now closed," "Celularity regains Nasdaq compliance after late filing," and "One U.S. partner will finish making Vesalius's peptide drug ingredients." A Form 13D/A filing dated 27 October is listed as a market wire item. One headline, "CELU Q4 2025 Earnings: Narrower-Than-Expected Loss Lifts Shares 6.85%," is flagged as RISK WATCH; it reports a narrower-than-expected loss while carrying a risk-watch label. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present.

• What are the company's specific products, indications, and revenue sources, given that the source data provides only a sector and industry classification?
• Why does FY 2024 show $0.7M in cash while FY 2025 shows $6.2M, and how is the company funding operating losses of $61.3M?
• Which debt obligations exist, given that debt is reported as N/A across all periods while Debt/Equity is listed as 0.5?
• What drove the revenue decline from $54.2M in FY 2024 to $26.6M in FY 2025, and what is the outlook for the partner relationship referenced in the news?
• What are the terms and details of the Nasdaq compliance items, and what are the implications of the Form 13D/A filing?